Publications

Search
Preclinical
PEGS
May 16, 2024
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
Dunja Urosev
Preclinical
PEGS
May 16, 2024
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and anti-tumor responses in hard-to-treat cancers
Newhook et al.
Preclinical
Festival of Biologics
April 17, 2024
Next Generation Trispecific T Cell Engagers (TriTCE) Designed to Improve Treatment Responses in Oncology
Genevieve Desjardins
Preclinical
AACR
April 10, 2024
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
Newhook et al.
Preclinical
AACR
April 10, 2024
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
Repenning et al.
Preclinical
AACR
April 8, 2024
Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates
Wong et al.
Preclinical
AACR
April 8, 2024
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
Barnscher et al.
ZW191
AACR
April 8, 2024
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
Lawn et al.
Preclinical
Molecular Cancer Therapeutics
February 14, 2024
Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates
Petersen et al.
Preclinical
PepTalk
January 17, 2024
Engineering a Pure and Stable Heterodimeric IgA for the Development of Multispecific Therapeutics
Meghan Verstraete
Preclinical
SITC
November 4, 2023
TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Newhook et al.
Preclinical
SITC
November 4, 2023
TriTCE CPI: a novel trispecific T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Verstraete et al.